Relationship between cardiac autonomic neuropathy and cardio-metabolic risk profile in adults with type 1 diabetes. (April 2021)

• Record Type: Journal Article
• Authors: Serdarova, M.; Dimova, R.; Chakarova, N.; Grozeva, G.; Todorova, A.; Tankova, T.
• Is Part Of: Diabetes research and clinical practice. Volume 174(2021)
• Publication Date: 2021-04
• Subjects: Type 1 diabetes -- Cardiac autonomic neuropathy -- Cardio-metabolic risk factors; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2021.108721
• Languages: English
• ISSNs: 0168-8227

Abstract

Highlights: Cardiovascular autonomic neuropathy (CAN) is common in type 1 diabetes (T1D). A number of modifiable metabolic risks factors are clinically important for CAN. Hypertension is a stronger risk factor for CAN than metabolic syndrome (MetS). More than two components of MetS increase the risk for CAN in T1D by 20%. Microvascular disease is a stronger predictor for CAN than any component of MetS. Abstract: Aim: The present study aims to determine the prevalence and association of cardiac autonomic neuropathy (CAN) with some traditional cardio-metabolic risk factors in adults with type 1 diabetes (T1D). Material and methods: 235 adults with T1D, divided into three groups according to diabetes duration, were recruited in this cross-sectional study from May 2017 till December 2018. Anthropometric parameters and blood pressure were measured. Lipids, liver enzymes, uric acid, creatinine, HbA1c and high sensitive C-reactive protein (hsCRP) were measured at fasting. Albumin/creatinine ratio (ACR) was measured in a first spot urine sample. Body composition was evaluated using bio-impedance analysis, Inbody720 (Biospace, USA). Advanced glycation end products (AGEs) were assessed by autofluorescence method, AGE Reader (Diagnoptics, The Netherlands). CAN was assessed by ANX-3.0 monitoring technology (ANSAR Medical Technologies, Inc., Philadelphia, PA), applying standard clinical tests. 2005 IDF and 2009 JIS definitions were used to define Metabolic Syndrome (MetS). Results: The prevalence of CAN was 23% and increased with diabetes duration. Sympathetic activity was independently related to age, albumin/creatinine ratio (ACR) and total body fat mass, and parasympathetic activity - to age and ACR. Elevated hsCRP, AGEs and body fat, diabetic retinopathy and nephropathy, as well as hypertension, dyslipidemia and metabolic syndrome were found to increase the risk of CAN in T1D. Conclusion: CAN appears to be a common complication of T1D, especially with longer duration, and is found to be related to diabetic microvascular disease and metabolic syndrome components.